Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction

Table 1

Vaccination coverage (VC) with meningococcal conjugate vaccines in children ≤24 months and adolescents in Italy and in the Puglia region, within 2006–2013 (postvaccination period), by birth cohort.

Birth cohort	Italy [10]		Puglia region
	Number of regions providing VC	MenC	MenC; VC	MenACWY; VC
			45.60%	1.80%
			51.20%	1.90%
			56.20%	2.10%
			62.00%	8.50%
			46.80%	4.70%
			37.30%	21.70%
			27.00%	32.30%
			24.70%	22.90%
2004^†			47.00%
2005^†	13	48.10%	65.00%
2006^†	13	58.50%	74.50%
2007^†	16	64.40%	77.90%
2008^†	16	68.30%	79.00%
2009^†	18	77.80%	81.90%
2010^†	18	81.10%	82.40%
2011^†			81.10%

Average VC in regions which provided data. ^†One dose of MenC conjugate vaccine at 15 months of age. One dose of MenC and, since 2012, of MenACWY conjugate vaccine at 11/12 years of age.